<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057705</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-101-13</org_study_id>
    <nct_id>NCT02057705</nct_id>
  </id_info>
  <brief_title>Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)</brief_title>
  <acronym>MTM</acronym>
  <official_title>Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valerion Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Myologie, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valerion Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-interventional, longitudinal study of the natural history and
      function of approximately 60 patients with MTM from the United States, Canada and Europe. The
      duration of the study, including the enrollment period, will be 36 months. Data from the
      study will be used to characterize the disease course of MTM and determine which outcome
      measures will be the best to assess the efficacy of potential therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-interventional, longitudinal study of the natural history and
      function of patients with MTM. The study duration is 36 months. The enrollment period will be
      12 months and each patient will be assessed over 24 months. Data will be analyzed at baseline
      and annually thereafter and reports will be prepared based on these analyses. A final report
      will summarize findings after all patients have completed 24 months of follow-up. Assessments
      performed in this study will be based on the age and ambulatory status of the patient. The
      assessments will also be adjusted to account for the variability in both phenotypes and age
      of the patients who may participate in this study. Patients will be evaluated at Baseline,
      Month 6, Month 12 and Month 24. It is anticipated that approximately 60 patients from the
      United States, Canada and Europe will be included in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 26, 2017</completion_date>
  <primary_completion_date type="Actual">June 26, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to characterize the disease course in MTM patients</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Study-specific functional assessments and patient questionnaires will be used and will be based on the age and ambulatory status of the participant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in disease severity and disease progression</measure>
    <time_frame>Baseline, Month 3 (EU only), Month 6, Month 12 and Month 24</time_frame>
    <description>Study-specific functional assessments and patient questionnaires will be used and will be based on the age and ambulatory status of the participant</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with an immune response against adeno-associated virus (AAV)</measure>
    <time_frame>Baseline Visit</time_frame>
    <description>A 5 ml sample of whole blood will be collected during the study to assess the immunity against various AAV serotypes.</description>
  </other_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Myotubular Myopathy</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  5 ml sample of whole blood will be collected during the study to assess the immunity
           against various AAV serotypes

        -  5 ml blood sample may be obtained for peripheral blood mononuclear cells (PBMC) to
           quantify X-linked myotubular myopathy gene 1 (MTM1) production

        -  24-hour urine collection will be performed every 6 months in order to measure urinary
           creatinine excretion

        -  Slides and tissue from a previously performed muscle biopsy will be obtained for a
           central review and quantification of histo- and immunohistopathological features of MTM
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Investigative Research Centers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients of any age (newborns included) may participate.

          -  Patients over 18 years of age and parent(s)/legal guardian(s) of patients &lt;18 years of
             age must provide written informed consent prior to participating in the study and
             informed assent will be obtained from minors at least 7 years of age when required by
             regulation.

          -  MTM resulting from a mutation in the MTM1 gene.

          -  Male or symptomatic female. A symptomatic female will be defined by the motor function
             assessment by Motor Function Measure (MFM) or North Star Ambulatory Assessment (NSAA)
             below 80% of the total score.

          -  Willing and able to comply with all protocol requirements and procedures.

        Exclusion criteria:

          -  Other disease which may significantly interfere with the assessment of MTM and is
             clearly not related to the disease.

          -  Currently enrolled in a treatment study; or treatment with an experimental therapy
             other than pyridostigmine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hal Landy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Valerion Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Children's Hospital, 300 Longwood Avenue</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children, 555 University Avenue</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme Mère Enfant, CHU Lyon Escale</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Salengro Hospital, CHU, Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Croix Rousse Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie, GH Pitié Salpêtrière, Bâtiment Babinski</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut I-Motion, Hôpital A. Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesù Children's Hospital</name>
      <address>
        <city>Rome</city>
        <zip>4-00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Puertas de Mar</name>
      <address>
        <city>Cadiz</city>
        <zip>21-11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/condition/x-linked-myotubular-myopathy</url>
    <description>National Institute of Health</description>
  </link>
  <link>
    <url>https://www.mda.org/disease/inherited-and-endocrine-myopathies</url>
    <description>Muscular Dystrophy Association</description>
  </link>
  <reference>
    <citation>Herman GE, Finegold M, Zhao W, de Gouyon B, Metzenberg A. Medical complications in long-term survivors with X-linked myotubular myopathy. J Pediatr. 1999 Feb;134(2):206-14.</citation>
    <PMID>9931531</PMID>
  </reference>
  <reference>
    <citation>Jungbluth H, Sewry CA, Buj-Bello A, Kristiansen M, Ørstavik KH, Kelsey A, Manzur AY, Mercuri E, Wallgren-Pettersson C, Muntoni F. Early and severe presentation of X-linked myotubular myopathy in a girl with skewed X-inactivation. Neuromuscul Disord. 2003 Jan;13(1):55-9.</citation>
    <PMID>12467733</PMID>
  </reference>
  <reference>
    <citation>McEntagart M, Parsons G, Buj-Bello A, Biancalana V, Fenton I, Little M, Krawczak M, Thomas N, Herman G, Clarke A, Wallgren-Pettersson C. Genotype-phenotype correlations in X-linked myotubular myopathy. Neuromuscul Disord. 2002 Dec;12(10):939-46.</citation>
    <PMID>12467749</PMID>
  </reference>
  <reference>
    <citation>Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis. 2008 Sep 25;3:26. doi: 10.1186/1750-1172-3-26. Review.</citation>
    <PMID>18817572</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2014</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MTM</keyword>
  <keyword>myotubular myopathy</keyword>
  <keyword>X-linked centronuclear myopathy</keyword>
  <keyword>inherited myopathies</keyword>
  <keyword>neuromuscular diseases</keyword>
  <keyword>hypotonia</keyword>
  <keyword>genetic mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Myopathies, Structural, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

